Faculty Opinions recommendation of Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718205974.793488589 ◽

2013 ◽

Author(s):

Kamran Ghoreschi

Keyword(s):

Monoclonal Antibody ◽

Controlled Trial ◽

Interleukin 12 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Get full-text (via PubEx)

Faculty Opinions recommendation of Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1108987.566149 ◽

2008 ◽

Author(s):

Johann Gudjonsson

Keyword(s):

Monoclonal Antibody ◽

Controlled Trial ◽

Interleukin 12 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Get full-text (via PubEx)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

The Lancet ◽

10.1016/s0140-6736(08)60726-6 ◽

2008 ◽

Vol 371 (9625) ◽

pp. 1675-1684 ◽

Cited By ~ 970

Author(s):

Kim A Papp ◽

Richard G Langley ◽

Mark Lebwohl ◽

Gerald G Krueger ◽

Philippe Szapary ◽

...

Keyword(s):

Monoclonal Antibody ◽

Controlled Trial ◽

Interleukin 12 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Get full-text (via PubEx)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

The Lancet ◽

10.1016/s0140-6736(08)60725-4 ◽

2008 ◽

Vol 371 (9625) ◽

pp. 1665-1674 ◽

Cited By ~ 1084

Author(s):

Craig L Leonardi ◽

Alexa B Kimball ◽

Kim A Papp ◽

Newman Yeilding ◽

Cynthia Guzzo ◽

...

Keyword(s):

Monoclonal Antibody ◽

Controlled Trial ◽

Interleukin 12 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Get full-text (via PubEx)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Yearbook of Dermatology and Dermatologic Surgery ◽

10.1016/s0093-3619(08)79142-1 ◽

2009 ◽

Vol 2009 ◽

pp. 145-146

Author(s):

B.H. Thiers

Keyword(s):

Monoclonal Antibody ◽

Controlled Trial ◽

Interleukin 12 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Get full-text (via PubEx)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Yearbook of Dermatology and Dermatologic Surgery ◽

10.1016/s0093-3619(08)79143-3 ◽

2009 ◽

Vol 2009 ◽

pp. 146-148

Author(s):

B.H. Thiers

Keyword(s):

Monoclonal Antibody ◽

Controlled Trial ◽

Interleukin 12 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Get full-text (via PubEx)

Faculty Opinions recommendation of Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1088945.542078 ◽

2007 ◽

Author(s):

Jonathan Schapiro

Keyword(s):

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Hiv 1

Get full-text (via PubEx)

Faculty Opinions recommendation of Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized,double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717847851.793453164 ◽

2012 ◽

Author(s):

Jonathon Truwit

Keyword(s):

Monoclonal Antibody ◽

Pseudomonas Aeruginosa ◽

Controlled Trial ◽

Antibody Fragment ◽

Double Blind ◽

Mechanically Ventilated ◽

Mechanically Ventilated Patients ◽

Double Blind Placebo ◽

Ventilated Patients

Get full-text (via PubEx)

Faculty Opinions recommendation of Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717958672.793516776 ◽

2016 ◽

Author(s):

Robin Spiller

Keyword(s):

Irritable Bowel Syndrome ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Irritable Bowel

Get full-text (via PubEx)

Faculty Opinions recommendation of Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718110070.793498413 ◽

2014 ◽

Author(s):

David Daikh

Keyword(s):

Monoclonal Antibody ◽

Ankylosing Spondylitis ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 17A

Get full-text (via PubEx)

Faculty Opinions recommendation of Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718524881.793498396 ◽

2014 ◽

Author(s):

David Daikh

Keyword(s):

Ankylosing Spondylitis ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Get full-text (via PubEx)